Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

REXN - Rexahn Pharmaceuticals Inc.

Close
1.81
-0.060   -3.315%

Share volume: 0
Last Updated: Thu 05 Nov 2020 10:00:01 PM CET
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
$1.87
-0.06
-3.21%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
29%
Profitability 31%
Dept financing 26%
Liquidity 24%
Performance 28%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$1.81
P/E Ratio 
N/A
DAY RANGE
$1.72 - $1.93
EPS 
-$6.27
52 WEEK RANGE
$1.70 - $3.70
52 WEEK CHANGE
$3.43
MARKET CAP 
2.029 M
YIELD 
N/A
SHARES OUTSTANDING 
1.121 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$1,118,315
AVERAGE 10 VOLUME 
$92,336
AVERAGE 30 VOLUME 
$78,021
Company detail
CEO: Douglas J. Swirsky
Region: US
Website: http://www.rexahn.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Recent news